Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 23 people, all of whom received a treatment called AMG 706. Twenty-two of the 23 participants completed the study, while one did not. The trial was primarily looking at two things: how many participants' tumours shrank or disappeared (called "objective tumour response"), and how many participants went six months without their disease getting worse (called "progression-free survival at 6 months"). It also tracked how long participants lived overall, how long it took for the disease to progress, and how many participants experienced serious unwanted effects. The reported data shows that, out of the 23 participants, 1 had a partial response — meaning their tumour shrank by at least 30% — and 0 had a complete response, meaning no one's tumours disappeared entirely. The trial was closed early because 4 participants experienced serious neurological (brain and nervous system) events, and as a result, the six-month progression-free survival figure and the duration of progression-free survival could not be reliably calculated and were not reported. The reported data shows a median overall survival — meaning the midpoint survival time across participants — of 13.1 months. Regarding serious unwanted effects (graded as severe or worse), the reported data shows varying numbers of participants experienced different types of serious effects, with figures ranging from 1 to 5 participants across the different categories recorded, though the specific labels for each category were not included in the submitted data. It is worth noting that the trial was stopped early due to serious neurological events observed in 4 participants, which the reported data acknowledges as the reason key outcome figures could not be fully collected. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back or not gone away after treatment, confirmed by a tissue sample (biopsy).
- Your cancer can be measured on a scan — at least one area of disease is large enough to be tracked over time.
- You have already received at least one chemotherapy treatment containing a platinum-based drug (such as carboplatin or cisplatin) for your cancer.
- Your cancer either came back within 12 months of platinum-based treatment, kept growing during that treatment, or never fully went away after it.
- You are physically well enough to carry out basic daily activities (confirm with trial site for exact fitness level required).
- Your blood counts, kidney function, liver function, and blood clotting levels are within acceptable ranges (confirm with trial site for exact values).
- You are not pregnant, not breastfeeding, and willing to use effective birth control if you could become pregnant.
- You are able to swallow pills or capsules.
- Your heart is functioning normally based on testing.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have fluid build-up around your lungs or in your abdomen that is causing significant shortness of breath.
- You have cancer that has spread to your brain that is not well-controlled.
- You have significant nerve damage affecting sensation or movement.
- You have had another serious cancer (other than certain skin cancers) in the past 5 years.
- You have had a heart attack, stroke, mini-stroke, heart failure, unstable chest pain, or significant heart rhythm problems in the past 12 months.
- You have uncontrolled high blood pressure (average reading of 150/90 or above), unless it is stable on medication.
- You have had a blood clot in an artery or vein in the past 12 months.
- You have a known bleeding disorder or problems with abnormal clotting within the past 14 days.
- You have open wounds, non-healing ulcers, or broken bones.
- You have an active infection that requires antibiotic treatment (other than a simple urinary tract infection).
- You are known to be positive for HIV, hepatitis B, or hepatitis C.
- You have had a previous allergic reaction to the study drug (AMG 706).
- You have previously received the study drug AMG 706.
- You are currently taking warfarin or similar blood thinners at doses above 1 mg per day.
- You have received certain targeted treatments (such as bevacizumab or other specific drugs that target blood vessel growth) recently — the required waiting periods vary by drug (confirm with trial site).
- You have received prior chemotherapy for cancers in the abdomen or pelvis other than ovarian, fallopian tube, or primary peritoneal cancer (with some exceptions for breast cancer treatment completed more than 3 years ago).
- You have a psychiatric or other condition that would prevent you from giving informed consent to participate.
- You are currently taking other experimental treatments or cancer treatments not part of this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0; Progression-free Survival (PFS) at 6 Months
Other options
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.